Eisai Announces Sponsorship of CURE Benefit to Support Epilepsy Research and
Former Secretary of State and Epilepsy Advocate Hillary Rodham Clinton to
Speak as This Year's Guest of Honor
WOODCLIFF LAKE, N.J., June 13, 2013
WOODCLIFF LAKE, N.J., June 13, 2013 /PRNewswire/ --Eisai Inc. announced today
its platinum level sponsorship of the Citizens United for Research in Epilepsy
(CURE) 15^th Annual Chicago Benefit taking place Thursday, June 13, at Navy
Pier, Chicago, IL.
(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )
CURE is a nonprofit organization focused on finding a cure for epilepsy by
raising research funds and increasing epilepsy awareness. The organization was
founded by Susan Axelrod, wife of David Axelrod, former senior advisor to
President Obama, whose daughter has epilepsy. Eisai, a company devoted to
human health care, has made epilepsy a therapeutic area of focus and is
committed to finding innovative solutions to satisfy unmet medical needs.
"CURE and Eisai have a common objective – to improve the lives of those
affected by epilepsy," said Christine Verini, vice president, Corporate
Communications & Advocacy at Eisai Inc. "We are proud to support CURE's
rigorous work to fund initiatives and research that may have a life-changing
impact on those people."
The event will recognize the Honorable Hillary Rodham Clinton, who, as First
Lady, was the driving force behind the first-ever National Institute of
Neurological Disorders and Stroke (NINDS) Conference on Curing Epilepsy in
2000. Last year, CURE's Chicago Benefit raised more than $1 million for
epilepsy research, and the organization hopes to exceed that amount this year.
"CURE's mission is not only driven by the pressing need for scientific
research and data, but by the painful struggle of families who suffer from
epilepsy worldwide," said Susan Axelrod, founding chair. "We appreciate
Eisai's commitment to these families and their support of crucial research
that can make meaningful improvements in the lives of millions."
Epilepsy is a medical condition that produces seizures affecting a variety of
mental and physical functions. According to the Institute of Medicine,
epilepsy is one of the most common neurological disorders, affecting 2.2
million people in the United States.
For more information about CURE, please visit http://www.cureepilepsy.org/.
At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co.,
Ltd., our passionate commitment to patient care is the driving force behind
our efforts to help address unmet medical needs. We are a fully integrated
pharmaceutical business with discovery, clinical, manufacturing and marketing
capabilities. Our key areas of commercial focus include oncology and specialty
care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more
about Eisai Inc., please visit us at www.eisai.com/US.
Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai's
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based
SOURCE Eisai Inc.
Contact: Laurie Landau, Eisai Inc., 201-746-2510, firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.